Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 7:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,834 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Diseases, Genetic Clear all
Completed Phase 3 Interventional

A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita

NCT05180708
View directory record Official record
Conditions
Pachyonychia Congenita
Interventions
QTORIN 3.9% rapamycin anhydrous gel, Vehicle
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Palo Alto, California • New Haven, Connecticut • Orange Park, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 16, 2026, 7:52 PM EDT
Active, not recruiting Phase 2 Interventional

Seal, Stopping Eczema and Allergy Study

NCT03742414
View directory record Official record
Conditions
Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis
Interventions
Tri-lipid skin barrier cream (Epiceram), Fluticasone propionate Cream 0.05%, Standard of Care
Combination Product · Other
Lead sponsor
Kari Nadeau, MD, PhD
Other
Eligibility
1 Week to 12 Weeks
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Palo Alto, California • Denver, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 16, 2026, 7:52 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Does the Cap Increase the Finding of Polyps When Water Exchange Colonoscopy is Used

NCT03566615
View directory record Official record
Conditions
Colonoscopy, Polyp of Colon
Interventions
CAP-straight, CAP-daisy, water
Device · Other
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
50 Years to 75 Years
Enrollment
1,630 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
2
States / cities
Mather, California • Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 16, 2026, 7:52 PM EDT
Recruiting Phase 1 Interventional

Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load

NCT06974877
View directory record Official record
Conditions
Cryopyrin-Associated Periodic Syndromes, Amyloidosis
Interventions
124I AT-01
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 16, 2026, 7:52 PM EDT
Completed Phase 1 Interventional Results available

A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis

NCT03775434
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Experimental: B244
Drug
Lead sponsor
AOBiome LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Bryant, Arkansas • Los Angeles, California • Plainfield, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 16, 2026, 7:52 PM EDT
Completed No phase listed Observational

Scratch and Sleep Quantification in Atopic Dermatitis

NCT03490877
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Sleep Disturbance
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
12 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 16, 2026, 7:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

NCT03310957
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
ladiratuzumab vedotin, Pembrolizumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 16, 2026, 7:52 PM EDT
Terminated Phase 3 Interventional Results available

Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta

NCT03638128
View directory record Official record
Conditions
Osteogenesis Imperfecta (OI)
Interventions
Denosumab, Alternative osteoporosis medications
Drug
Lead sponsor
Amgen
Industry
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Los Angeles, California • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 16, 2026, 7:52 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Probiotic Supplementation in Breastfed Newborn Infants

NCT02286999
View directory record Official record
Conditions
Atopic Dermatitis, Food Allergies
Interventions
B. infantis, Placebo
Drug
Lead sponsor
Emanual Maverakis, MD
Other
Eligibility
1 Day to 7 Days
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 16, 2026, 7:52 PM EDT
Completed No phase listed Observational

A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)

NCT02294877
View directory record Official record
Conditions
Mucopolysaccharidosis IV Type A, Morquio A Syndrome, MPS IVA
Interventions
Vimizim® (elosulfase alfa)
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
Not listed
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 16, 2026, 7:52 PM EDT
Completed Phase 3 Interventional Results available

Open-label Study of Dupilumab in Patients With Atopic Dermatitis

NCT01949311
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
129
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 16, 2026, 7:52 PM EDT
Completed Not applicable Interventional

The Genetic Education for Men Trial: Web-Based Education vs. Standard Care

NCT02957981
View directory record Official record
Conditions
Prostate Carcinoma, Breast Neoplasm, Pancreatic Cancer, BRCA1 Mutation, BRCA2 Mutation
Interventions
Web-based Counseling, Standard Care
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
25 Years to 70 Years · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 16, 2026, 7:52 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease

NCT04088734
View directory record Official record
Conditions
MPS IIIA, Sanfilippo Syndrome, Sanfilippo A, Mucopolysaccharidosis III
Interventions
ABO-102
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
2 Years to 18 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 16, 2026, 7:52 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

NCT04032704
View directory record Official record
Conditions
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
Interventions
ladiratuzumab vedotin, pembrolizumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
27
States / cities
Chandler, Arizona • Los Angeles, California • Santa Rosa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 16, 2026, 7:52 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Allergic Disease Onset Prevention Study

NCT05003804
View directory record Official record
Conditions
Atopic Dermatitis, Type 1 Hypersensitivity
Interventions
STMC-103H, Placebo
Biological
Lead sponsor
Siolta Therapeutics, Inc.
Industry
Eligibility
0 Days to 14 Days
Enrollment
283 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
24
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 16, 2026, 7:52 PM EDT
Completed No phase listed Observational

Decision-making Regarding Prophylactic Mastectomy and Oophorectomy in Women Seeking Genetic Counseling and Testing for BRCA1/2 Mutations

NCT00579007
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
telephone interviews
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
25 Years and older · Female only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 16, 2026, 7:52 PM EDT
Completed No phase listed Observational

Microarray Analysis for Human Genetic Disease

NCT00001898
View directory record Official record
Conditions
Breast Neoplasm, Hereditary Neoplastic Syndrome, Melanoma, Ovarian Neoplasm
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
5
States / cities
Tucson, Arizona • Baltimore, Maryland • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 16, 2026, 7:52 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT03736967
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
REGN3500, Dupilumab, REGN3500 + Dupilumab Combo, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
22
States / cities
Phoenix, Arizona • Fountain Valley, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 16, 2026, 7:52 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of AIN457 in Noninfectious Uveitis

NCT00685399
View directory record Official record
Conditions
Non-infectious Uveitis
Interventions
AIN457, AIN 457
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
20
States / cities
Beverly Hills, California • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 16, 2026, 7:52 PM EDT
Completed Phase 4 Interventional Results available

Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis

NCT00693693
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
hydrocortisone 17-butyrate 0.1% Cream preparation, hydrocortisone 17-butyrate 0.1% Ointment preparation, hydrocortisone 17-butyrate 0.1% Lipocream preparation
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 16, 2026, 7:52 PM EDT
Completed Phase 1 Interventional

Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita

NCT00716014
View directory record Official record
Conditions
Pachyonychia Congenita
Interventions
TD101, Normal saline (placebo)
Drug
Lead sponsor
Pachyonychia Congenita Project
Other
Eligibility
10 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 19, 2008 · Synced Oct 16, 2026, 7:52 PM EDT
Completed Phase 4 Interventional Results available

SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"

NCT04033367
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
8
States / cities
North Little Rock, Arkansas • Redwood City, California • Rolling Hills Estates, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 16, 2026, 7:52 PM EDT
Available No phase listed Expanded access

Expanded Access Program of Bitopertin For Participants With EPP or XLP

NCT07603401
View directory record Official record
Conditions
Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
Interventions
DISC-1459
Drug
Lead sponsor
Disc Medicine, Inc
Industry
Eligibility
12 Years and older
U.S. locations
7
States / cities
Miami, Florida • Boston, Massachusetts • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 16, 2026, 7:52 PM EDT
Completed No phase listed Observational

Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer

NCT01139957
View directory record Official record
Conditions
Breast Carcinoma, Fallopian Tube Carcinoma, Ovarian Neoplasm, Primary Peritoneal Carcinoma
Interventions
Evaluation of Cancer Risk Factors, Quality-of-Life Assessment, Questionnaire Administration, Study of High Risk Factors
Procedure · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
30 Years and older · Female only
Enrollment
1,916 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
141
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 106 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 16, 2026, 7:52 PM EDT